CN1795186A

CN1795186A - Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5

Info

Publication number: CN1795186A
Application number: CNA2004800145607A
Authority: CN
Inventors: N·D·P·科斯福德; J·R·罗普; L·R·特拉尼; 王波维
Original assignee: Merck and Co Inc
Current assignee: Merck and Co Inc
Priority date: 2003-04-04
Filing date: 2004-03-31
Publication date: 2006-06-28
Anticipated expiration: 2024-03-31
Also published as: AU2004227833A1; AU2004227833B2; EP1613617A2; WO2004089306A2; EP1613617A4; US20070082067A1; CN100537564C; WO2004089306A3; JP2006522131A; US7268151B2; CA2521396A1

Abstract

Provided are novel triazole compounds represented by Formula (1): (where A, A<1>, A<2>, A<3>, A<4>, A<5>, B, R<11>, W, X, Y and Z are as defined herein) in which the triazole is substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.

Description

The aryl substituted triazole modulators of metabotropic glutamate receptor-5

Background of invention

Invention field

The present invention relates to triazole compounds, these triazole compounds are replaced by following radicals: i) heteroaryl ring, and ii) another heteroaryl ring or aryl rings, wherein at least one ring in these rings is further replaced by another ring.Specifically, the present invention relates to triazole compounds direct substitution or that replace by bridge: the heteroaryl moieties that i) contains the N adjacent with the heteroaryl tie point by following radicals; Ii) another heteroaryl ring or aryl rings, wherein at least one ring in these rings is further replaced by another ring, these compounds are conditioning agents of metabotropic glutamate receptor-hypotype 5 (" mGluR5 "), be used for the treatment of for example schizophrenia, anxiety disorder, dysthymia disorders, panic disorder, mental disorder and mood disorders such as bipolar disorder and diel rhythm obstacle also are used for the treatment of pain, Parkinson's disease (Parkinson ' s disease), cognition dysfunction, epilepsy, dopy, drug abuse, drug withdrawal syndrome (drug withdrawal), obesity and other disease.

Background context

A main excitatory neurotransmitter in the mammalian nervous system is the L-glutamic acid molecule, and this molecular energy combines with neurone, thus the activating cells surface receptor.These surface receptors or be feature with the ionic glutamate receptor, or be feature with the metabotropic glutamate receptor.Metabotropic glutamate receptor (" mGluR ") is a g protein coupled receptor, can activate second messenger system in the born of the same parents when combining with L-glutamic acid.The activation of mGluR can cause the various kinds of cell reaction.Particularly mGluR1 and mGluR5 activate Phospholipase C, thereby make the cellular calcium mobilization.

To the adjusting of metabotropic glutamate receptor hypotype 5 (mGluR5) can be used for treating the system of affecting the nerves disease (referring to for example W.P.J.M Spooren etc., Trends Pharmacol.Sci., 22: 331-337 (2001) and the reference of wherein quoting).For example, up-to-date evidence confirms that mGluR5 participates in the nociception process, and regulate mGluR5 with the mGluR5 alternative cpd and can be used for treating various pain statuses, comprise acute pain, rest pain and chronic pain [K Walker etc., Neuropharmacology 40: 1-9 (2001); F.Bordi, A.Ugolini Brain Res., 871: 223-233 (2001)], inflammatory pain [K Walker etc., Neuropharmacology, 40: 10-19 (2001); Bhave etc., Nature Neurosci. 4: 417-423 (2001)] and neuropathic pain [Dogrul etc., Neurosci.Lett. 292: 115-118 (2000)].

Further the evidence support is used the mGluR5 conditioning agent and is treated mental disorder and neurological disorder.For example, in the animal model of the mood disorder that comprises anxiety disorder and dysthymia disorders, the mGluR5 alternative cpd, for example 2-methyl-6-(phenylacetylene)-pyridine (" MPEP ") be effectively [W.P.J.M Spooren etc., J.Pharmacol.Exp.Ther., 295: 1267-1275 (2000); E.Tatarczynska etc., Brit.J.Pharmacol.. 132: 1423-1430 (2001); A.Klodzynska etc., Pol.J.Pharmacol., 132: 1423-1430 (2001)].The Human genome expression data shows, to the adjusting of mGluR5 can be used for treating schizophrenia [T.Ohnuma etc., Mol.Brain.Res., 56: 207-217 (1998); Ibid, Mol.Brain.Res., 85: 24-31 (2000)].Research also shows, the effect of mGluR5 and potential utility [W.P.J.MSpooren etc., the Europ.J.Pharmacol. that mGluR5 regulates compound when treating dyskinesia such as Parkinson's disease for example 406.:403-410 (2000); H.Awad etc., J.Neurosci. 20: 7871-7879 (2000); K.Ossawa etc., Neuropharmacol. 41: 413-420 (2001)].Other research supports mGluR5 to be adjusted in the effect in the following disease of treatment: cognition dysfunction [G.Riedel etc., Neuropharmacol. 39: 1943-1951 (2000)], epilepsy [A.Chapman etc., Neuropharmacol. 39: 1567-1574 (2000)] and neuroprotective disease [V.Bruno etc., Neuropharmacol. 39: 2223-2230 (2000)].The research of mGluR5 knock-out mice and MPEP is also pointed out, and the adjusting of these acceptors be can be used for treating dopy, drug abuse and drug withdrawal syndrome [C.Chiamulera etc., NatureNeurosci. 4: 873-874 (2001)].

International Patent Publication No. W WO 01/12627 and WO 99/26927 have described assorted polynuclear compound and as the purposes of metabotropic glutamate receptor antagonists.

S.Kamiya etc., Chem.Pharm.Bull., 38 (12): 3226-3229 (1990) has described 1-(4-p-methoxy-phenyl)-3-pyridyl-5-hydroxyl-triazole and 1-phenyl-3-pyridyl-5-hydroxyl-triazole.

United States Patent (USP) the 3rd, 647 has been described pyridyl-1,2,4-oxadiazole derivative No. 809.United States Patent (USP) the 4th, 022 has been described 3-pyridyl-5-isothiocyano Ben oxadiazole No. 901.International Patent Publication No. W WO 98/17652 describes oxadiazole, and WO 97/03967 has described various replacement aromatic substance, and WO 94/22846 has described various heterogeneous ring compounds.

Many researchists have described the compound that comprises ring system that is effective in many therepic use.For example, International Patent Publication No. W WO 98/25883 has described the ketone benzamide as calpain inhibitor; European patent publication EP 811610 and U.S. Patent number 5,679,712,5,693,672 and 5,747,541 have described substituted benzene formyl guanidine sodium channel blockers; United States Patent (USP) the 5th, 736 has been described the ring system as photosensitive composition for No. 297.

Yet, still need in treatment, suppress novel cpd and the novel compositions of mGluR5 with minimal side effect.

Summary of the invention

The present invention relates to new triazole compounds by following formula (I) expression:

(wherein A, A ¹, A ², A ³, A ⁴, A ⁵, B, R ¹¹, W, X, Y and Z as defined herein) wherein triazole is direct substitution or replace by bridge by following radicals: the heteroaryl moieties that i) contains the N adjacent with the heteroaryl tie point; Ii) another heteroaryl ring or aryl rings, wherein at least one ring in these rings is further replaced by another ring, these compounds are metabotropic glutamate receptor-hypotype 5 conditioning agents, be used for the treatment of for example schizophrenia, anxiety disorder, dysthymia disorders, mental disorder such as bipolar disorder and panic disorder and mood disorder also are used for the treatment of pain, Parkinson's disease, cognition dysfunction, epilepsy, diel rhythm obstacle and somnopathy---the somnopathy and the jet lag that bring out of break tour for example, dopy, drug abuse, drug withdrawal syndrome, obesity and other disease.The present invention also provides a kind of pharmaceutical composition, and described composition comprises the new triazole compounds that is replaced by heteroaryl moieties and the medicine acceptable carrier of significant quantity.

The present invention also provides for example method of mental disorder such as schizophrenia, anxiety disorder, dysthymia disorders, panic disorder, bipolar disorder and diel rhythm obstacle and somnopathy and mood disorder for the treatment of, and treatment pain, Parkinson's disease, cognition dysfunction, epilepsy, obesity, dopy, drug abuse and the syndromic method of drug withdrawal, described method comprises the new triazole compounds that is replaced by heteroaryl moieties that gives significant quantity.

Detailed Description Of The Invention

Compound of the present invention or the acceptable salt of its medicine are represented by following formula (I):

Wherein:

X and Y are aryl or heteroaryl independently of one another, and wherein at least one among X and the Y is the heteroaryl that contains adjacent with the link position of A or B respectively N;

A ¹, A ², A ³, A ⁴And A ⁵In three be N, remaining is C, and A ¹And A ⁴One must be N, but A ¹And A ⁴Be not N simultaneously;

W is-C _3-7Cycloalkyl ,-assorted C _3-7Cycloalkyl ,-C _0-6Alkylaryl or-C _0-6Miscellaneous alkyl aryl, they are optional separately by 1-7 independently following substituting group replacement: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _1-6Thiazolinyl ,-C _1-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ²

X is optional to be replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

R ¹, R ²And R ³Be independently of one another-C _0-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; Wherein any is optional by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

R ⁴For-C _1-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; They are optional separately by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

A is-C _0-4Alkyl ,-C _0-2Alkyl-SO-C _0-2Alkyl-,-C _0-2Alkyl-SO ₂-C _0-2Alkyl-,-C _0-2Alkyl-CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ⁹CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ⁹SO ₂-C _0-2Alkyl-or-assorted C _0-4Alkyl;

Y is optional to be replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ⁵,-NR ⁵R ⁶,-C (=NR ⁵) NR ⁶R ⁷,-N (=NR ⁵) NR ⁶R ⁷,-NR ⁵COR ⁶,-NR ⁵CO ₂R ⁶,-NR ⁵SO ₂R ⁸,-NR ⁵CONR ⁶R ⁷,-SR ⁸,-SOR ⁸,-SO ₂R ⁸,-SO ₂NR ⁵R ⁶,-COR ⁵,-CO ₂R ⁵,-CONR ⁵R ⁶,-C (=NR ⁵) R ⁶Or-C (=NOR ⁵) R ⁶, wherein optional two substituting groups are combined together to form and Y condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

R ⁵, R ⁶And R ⁷Be independently of one another-C _0-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; Wherein any is optional by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

R ⁸For-C _1-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; They are optional separately by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

B is-C _0-4Alkyl ,-C _0-2Alkyl-SO-C _0-2Alkyl-,-C _0-2Alkyl-SO ₂-C _0-2Alkyl-,-C _0-2Alkyl-CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ¹⁰CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ¹⁰SO ₂-C _0-2Alkyl-or-assorted C _0-4Alkyl;

R ⁹And R ¹⁰Be independently of one another-C _0-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; Wherein any is optional by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) ,-N (C _0-6Alkyl) (aryl);

Z is-C _3-7Cycloalkyl ,-assorted C _3-7Cycloalkyl ,-C _0-6Alkylaryl or-C _0-6Miscellaneous alkyl aryl, they are optional separately by 1-7 independently following substituting group replacement: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _1-6Thiazolinyl ,-C _1-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ²

R ¹¹For halogen ,-C _0-6Alkyl ,-C _0-6Alkoxyl group ,=O ,=N (C _0-4Alkyl) or-N (C _0-4Alkyl) (C _0-4Alkyl);

Any alkyl is optional by 1-5 independently halogenic substituent replacement;

Any N can be the N-oxide compound; With

One of W and Z are optional not to be existed.

In one embodiment, compound of the present invention or the acceptable salt of its medicine are by formula (I) expression, wherein:

X is the optional 2-pyridyl that is replaced by 1-4 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

R ¹, R ²And R ³Be independently of one another-C _0-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; Wherein any is optional by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) ,-N (C _0-6Alkyl) (aryl);

R ⁴For-C _1-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; They are optional separately by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) ,-N (C _0-6Alkyl) (aryl);

A is-C _0-4Alkyl ,-C _0-2Alkyl-SO-C _0-2Alkyl-,-C _0-2Alkyl-SO ₂-C _0-2Alkyl-,-C _0-2Alkyl-CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ⁹CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ¹SO ₂-C _0-2Alkyl-or-assorted C _0-4Alkyl;

Y is optional aryl or the heteroaryl that is replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ⁵,-NR ⁵R ⁶,-C (=NR ⁵) NR ⁶R ⁷,-N (=NR ⁵) NR ⁶R ⁷,-NR ⁵COR ⁶,-NR ⁵CO ₂R ⁶,-NR ⁵SO ₂R ⁸,-NR ⁵CONR ⁶R ⁷,-SR ⁸,-SOR ⁸,-SO ₂R ⁸,-SO ₂NR ⁵R ⁶,-COR ⁵,-CO ₂R ⁵,-CONR ⁵R ⁶,-C (=NR ⁵) R ⁶Or-C (=NOR ⁵) R ⁶, wherein optional two substituting groups are combined together to form and Y condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

R ⁵, R ⁶And R ⁷Be independently of one another-C _0-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; Wherein any is optional by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) ,-N (C _0-6Alkyl) (aryl);

R ⁸For-C _1-6Alkyl ,-C _3-7Cycloalkyl, heteroaryl or aryl; They are optional separately by 1-5 independently following substituting group replacement: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) ,-N (C _0-6Alkyl) (aryl);

B is-C _0-4Alkyl ,-C _0-2Alkyl-SO-C _0-2Alkyl-,-C _0-2Alkyl-SO ₂-C _0-2Alkyl-,-C _0-2Alkyl-CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ¹⁰CO-C _0-2Alkyl-,-C _0-2Alkyl-NR ¹SO ₂-C _0-2Alkyl-or-assorted C _0-4Alkyl;

Any alkyl is optional by 1-5 independently halogenic substituent replacement;

Any N can be the N-oxide compound; With

One of W and Z are optional not to be existed.

In another embodiment, compound of the present invention or the acceptable salt of its medicine are by formula (I) expression, wherein:

X is optional aryl or the heteroaryl that is replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

Y is the optional phenyl that is replaced by 1-5 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ⁵,-NR ⁵R ⁶,-C (=NR ⁵) NR ⁶R ⁷,-N (=NR ⁵) NR ⁶R ⁷,-NR ⁵COR ⁶,-NR ⁵CO ₂R ⁶,-NR ⁵SO ₂R ⁸,-NR ⁵CONR ⁶R ⁷,-SR ⁸,-SOR ⁸,-SO ₂R ⁸,-SO ₂NR ⁵R ⁶,-COR ⁵,-CO ₂R ⁵,-CONR ⁵R ⁶,-C (=NR ⁵) R ⁶Or-C (=NOR ⁵) R ⁶, wherein optional two substituting groups are combined together to form and Y condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

Any alkyl is optional by 1-5 independently halogenic substituent replacement;

Any N can be the N-oxide compound; With

One of W and Z are optional not to be existed.

X for optional by the aryl or the heteroaryl of 1-7 independently following group replacement: hydrogen, halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl);

Z chooses wantonly by 1-7 independently following substituting group to replace-C _0-6Miscellaneous alkyl aryl: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _1-6Thiazolinyl ,-C _1-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ²

Any alkyl is optional by 1-5 independently halogenic substituent replacement;

Any N can be the N-oxide compound; With

One of W and Z are optional not to be existed.

X is the optional 2-pyridyl that is replaced by 1-4 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl); With

Y is optional aryl or the heteroaryl that is replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ⁵,-NR ⁵R ⁶,-C (=NR ⁵) NR ⁶R ⁷,-N (=NR ⁵) NR ⁶R ⁷,-NR ⁵COR ⁶,-NR ⁵CO ₂R ⁶,-NR ⁵SO ₂R ⁸,-NR ⁵CONR ⁶R ⁷,-SR ⁸,-SOR ⁸,-SO ₂R ⁸,-SO ₂NR ⁵R ⁶,-COR ⁵,-CO ₂R ⁵,-CONR ⁵R ⁶,-C (=NR ⁵) R ⁶Or-C (=NOR ⁵) R ⁶, wherein optional two substituting groups are combined together to form and Y condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl).

In one embodiment of the invention, compound of the present invention or the acceptable salt of its medicine are by formula (I) expression, wherein:

X is optional aryl or the heteroaryl that is replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl); With

Y is the optional phenyl that is replaced by 1-5 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ⁵,-NR ⁵R ⁶,-C (=NR ⁵) NR ⁶R ⁷,-N (=NR ⁵) NR ⁶R ⁷,-NR ⁵COR ⁶,-NR ⁵CO ₂R ⁶,-NR ⁵SO ₂R ⁸,-NR ⁵CONR ⁶R ⁷,-SR ⁸,-SOR ⁸,-SO ₂R ⁸,-SO ₂NR ⁵R ⁶,-COR ⁵,-CO ₂R ⁵,-CONR ⁵R ⁶,-C (=NR ⁵) R ⁶Or-C (=NOR ⁵) R ⁶, wherein optional two substituting groups are combined together to form and Y condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl).

Y is optional aryl or the heteroaryl that is replaced by 1-7 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ⁵,-NR ⁵R ⁶,-C (=NR ⁵) NR ⁶R ⁷,-N (=NR ⁵) NR ⁶R ⁷,-NR ⁵COR ⁶,-NR ⁵CO ₂R ⁶,-NR ⁵SO ₂R ⁸,-NR ⁵CONR ⁶R ⁷,-SR ⁸,-SOR ⁸,-SO ₂R ⁸,-SO ₂NR ⁵R ⁶,-COR ⁵,-CO ₂R ⁵,-CONR ⁵R ⁶,-C (=NR ⁵) R ⁶Or-C (=NOR ⁵) R ⁶, wherein optional two substituting groups are combined together to form and Y condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl); With

R ¹¹For halogen ,-C _0-6Alkyl ,-C _0-6Alkoxyl group ,=O ,=N (C _0-4Alkyl) or-N (C _0-4Alkyl) (C _0-4Alkyl).

The group that " alkyl " used herein and other have a prefix " alkane (alk) " is alkoxyl group, alkyloyl, thiazolinyl, alkynyl or the like for example, is meant it can is the carbochain of straight or branched or its combination.The example of alkyl comprises methyl, ethyl, propyl group, sec.-propyl, butyl, sec-butyl, the tertiary butyl, amyl group, hexyl, heptyl etc." thiazolinyl ", " alkynyl " and other similar terms comprise the carbochain that contains at least one unsaturated C-C key.

Term " group " and " substituting group " are used interchangeably in this application.

Term " cycloalkyl " is meant and does not contain heteroatomic carbocyclic ring, and comprises monocycle, two ring and trinucleated saturated carbon ring and condensed ring systems.This condensed ring system can comprise a partially or completely undersaturated ring, and phenyl ring for example is to form condensed ring system, for example benzo-fused carbocyclic ring.Cycloalkyl comprises the condensed ring system as spiral shell condensed ring system one class.The example of cycloalkyl comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, naphthalane, diamantane, indanyl, indenyl, fluorenyl, 1,2,3,4-tetralin etc.Equally, " cycloalkenyl group " is meant the carbocyclic ring that does not contain heteroatoms but contain the two keys of at least one non-aromatics C-C, and comprises monocycle, two ring and trinucleated fractional saturation carbocyclic rings, and benzo-fused cycloolefin.The example of cycloalkenyl group comprises cyclohexenyl, indenyl etc.

Term " aryl " refers to aromatic substituent, is monocycle or fused polycycle.If be made of many rings, then at least one makeup ring is an aromatic ring.The preferred aryl groups substituting group is phenyl and naphthyl.

Term " cycloalkyloxy " otherwise comprises by short C except as otherwise noted _1-2Length is connected the cycloalkyl that atom links to each other with oxygen.

Term " C _0-6Alkyl " comprise the alkyl that contains 6,5,4,3,2,1 or zero carbon atom.The alkyl of zero carbon atom then is chemical bond when alkyl is the hydrogen atom substituting group during for end group when alkyl is bridging group.

Term " is mixed " except as otherwise noted, otherwise comprises one or more O, S or N atom.For example, Heterocyclylalkyl and heteroaryl comprise the ring system that contains one or more O, S or N atom in the ring, comprise the mixing atom of this type of atom.Heteroatoms D-loop carbon atom.Therefore, heterocycle C for example ₅Alkyl is to contain the 5 yuan rings of 4 carbon atoms to the zero carbon atom.The example of heteroaryl comprises pyridyl, quinolyl, isoquinolyl, pyridazinyl, pyrimidyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuran group, thienyl, benzothienyl, pyrryl, indyl, pyrazolyl, indazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl-, oxadiazole base, thiadiazolyl group, triazolyl and tetrazyl.The example of Heterocyclylalkyl comprises azelidinyl, pyrrolidyl, piperidyl, piperazinyl, morpholinyl, tetrahydrofuran base, imidazolinyl, pyrrolidin-2-one, piperidines-2-ketone and thio-morpholinyl.

Term " assorted C _0-4Alkyl " be meant the assorted alkyl that contains 3,2,1 carbon atoms or zero carbon atom.Yet, essential at least one heteroatoms that exists.Therefore, as an example, carbon atoms but contain the assorted C of a N atom not _0-4Alkyl, bridging group then is-NH-in this way, end group then is-NH in this way ₂For O or S heteroatoms, similarly bridging group or end group also are clear and definite.

Term " amine " otherwise comprises by C except as otherwise noted _0-6Primary amine, secondary amine and tertiary amine that alkyl replaces.

Term " carbonyl " otherwise comprises C during for end group when carbonyl except as otherwise noted _0-6Alkyl substituent.

Term " halogen " comprises fluorine atom, chlorine atom, bromine atoms and iodine atom.

Term " the optional replacement " is meant and both comprises that replacement does not comprise replacement yet.Therefore, for example optional substituted aryl can be represented penta fluoro benzene ring or phenyl ring.In addition, optional replace a plurality of parts, alkylaryl for example is meant that alkyl and aryl are optional the replacement.If have only one to replace in a plurality of parts for optional, then should specify, alkylaryl for example, wherein aryl is by halogen or hydroxyl is optional replaces.

Compound described herein comprises one or more pairs of keys, therefore can produce suitable/trans isomer and other conformer.The present invention includes all these possible isomer and these mixture of isomers.

Compound described herein can comprise one or more asymmetric centers, therefore can produce diastereomer and optically active isomer.The present invention includes all these possible diastereomers and their racemic mixture, their pure substantially fractionation enantiomorph, all possible geometrical isomer and the acceptable salt of medicine thereof.Following formula I does not provide definite stereochemistry on some position.The present invention includes all steric isomers of formula I and the acceptable salt of medicine thereof.In addition, the mixture and the isolating concrete steric isomer that have also comprised steric isomer.In the building-up process that is used for preparing this compounds, perhaps in using racemization well known by persons skilled in the art or epimeric process, the product of these processes can be the mixture of steric isomer.

Term " the acceptable salt of medicine " is meant the salt by acceptable nontoxic alkali of medicine or non-toxic acid preparation.If it is acid that compound of the present invention is, then its corresponding salt can be prepared by the acceptable nontoxic alkali of medicine (comprising mineral alkali and organic bases) easily.Salt derived from this type of mineral alkali comprises aluminium salt, ammonium salt, calcium salt, mantoquita (mantoquita and cuprous salt), molysite, ferrous salt, lithium salts, magnesium salts, manganese salt (manganic salt and manganese salt), sylvite, sodium salt, zinc salt etc.Particularly preferably be ammonium salt, calcium salt, magnesium salts, sylvite and sodium salt.Salt derived from the acceptable organic nontoxic alkali of medicine comprises primary amine salt, secondary amine salt and tertiary ammonium salt, also has cyclammonium salt and replaces amine salt, and for example naturally occurring replacement amine salt and synthetic replace amine salt.But the acceptable organic nontoxic alkali of the salifiable other medicines of shape comprises ion exchange resin, arginine for example, trimethyl-glycine, caffeine, choline, N, N '-dibenzyl-ethylenediamin, diethylamine, 2-diethylaminoethanol, the 2-dimethylaminoethanol, thanomin, quadrol, N-ethylmorpholine, N-ethylpiperidine, glycosamine (glucamine), glucosamine (glucosamine), Histidine, sea crust amine (hydrabamine), Isopropylamine, Methionin, methylglucosamine, morpholine, piperazine, piperidines, versamid 900, PROCAINE HCL, PHARMA GRADE, purine, Theobromine, triethylamine, Trimethylamine 99, tripropyl amine, Trometamol etc.

If compound of the present invention is alkalescence, its corresponding salt can prepare from the acceptable non-toxic acid of medicine (comprising mineral acid and organic acid) easily.This type of acid comprises for example acetate, Phenylsulfonic acid, phenylformic acid, camphorsulfonic acid, citric acid, ethyl sulfonic acid, fumaric acid, glyconic acid, L-glutamic acid, Hydrogen bromide, hydrochloric acid, isethionic acid, lactic acid, toxilic acid, oxysuccinic acid, amygdalic acid, methylsulfonic acid, glactaric acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succsinic acid, sulfuric acid, tartrate, tosic acid etc.Particularly preferably be citric acid, Hydrogen bromide, hydrochloric acid, toxilic acid, phosphoric acid, sulfuric acid and tartrate.

Pharmaceutical composition of the present invention comprises the compound of being represented by formula I (or the acceptable salt of its medicine) as activeconstituents, medicine acceptable carrier and optional other therapeutic component or auxiliary material.This additional treatment composition comprises for example i) opiate agonist or antagonist, ii) calcium-channel antagonists, iii) 5HT receptor stimulant or antagonist, iv) sodium channel antagonist, v) nmda receptor agonist or antagonist, vi) COX-2 selective depressant, vii) NK1 antagonist, viii) NSAID (non-steroidal anti-inflammatory drug) (" NSAID "), ix) GABA-A receptor modulators, x) dopamine agonist or antagonist, xi) selectivity serotonin reuptake inhibitor (" SSRI ") and/or selectivity serotonin and norepinephrine reuptake inhibitor (" SSNRI "), xii) tricyclic antidepressant, xiv) norepinephrine conditioning agent, xv) L-DOPA, xvi) buspirone, xvii) lithium salts, xviii) valproate, ixx) gabapentin (neurontin, gabapentin), xx) olanzapine, xxi) comprise the nicotinic agonist or the antagonist of Nicotine, xxii) muscarinic agonist or antagonist, xxiii) heroine substitutes for example methadone of medicine, left-handed-α-Methadyl Acetate; buprenorphine and TREXUPONT, xxiv) abstinence from alcohol sulphur and acamprosate.Described composition comprises the composition that is applicable to oral, rectum, part and parenteral (comprising subcutaneous, intramuscular and intravenously) administration, but in any case, the only approach of delivery of active ingredients will depend on the character and the severity of concrete host and illness.Described pharmaceutical composition can be unit dosage easily, and can prepare with the well-known any method of pharmaceutical field.

The ointment, ointment, gelifying agent, solution or the suspensoid that contain formula I compound use applicable to the part.For the present invention, also comprise mouth wash shua and gargle in the local scope of using.

Dosage level is that about 0.01mg/kg body weight/day is to about 140mg/kg body weight/day, can be used for treating for example mental disorder and mood disorders such as schizophrenia, anxiety disorder, dysthymia disorders, panic disorder, bipolar disorder and diel rhythm obstacle, and can be used for treating mGluR5 is suppressed the pain that responds, perhaps dosage level is every patient's every day of about 0.5mg about 7g extremely.For example, schizophrenia, anxiety disorder, dysthymia disorders and panic disorder can by by the described compound of every kg body weight about 0.01mg to 75mg every day or every patient every day about 0.5mg effectively treat to the described compound of about 3.5g.Pain can by by the described compound of every kg body weight about 0.01mg to 125mg every day or every patient every day about 0.5mg effectively treat to about 5.5g.In addition, people know that mGluR5 of the present invention suppresses compound and can give by prevention effective dose level, to prevent above-mentioned illness.

The activeconstituents consumption for preparing one-pack type with the solid support material coupling will change with host to be treated and concrete administering mode.For example, the human body oral medicinal preparation can contain the 0.5mg that has an appointment easily to the promoting agent of about 5g, and mixes with an amount of solid support material, and the consumption of this solid support material can account for about 5% to about 95% of total composition.Unit dosage generally contains the extremely activeconstituents of about 1000mg of 1mg of having an appointment, and typically is 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg or 1000mg.

Yet, people know, any concrete patient's accurate dosage level will depend on various factors, comprise age, body weight, general health situation, sex, diet, administration time, route of administration, excretion rate, drug regimen and the severity of the disease specific of being treated.

In practice, can the present invention be mixed and made into uniform mixture by compound or the acceptable salt of its medicine that formula I represents as activeconstituents and pharmaceutical carrier according to conventional pharmaceutical technology.Carrier can be various form, and this depends on the dosage form that administration is required, for example oral or parenteral (comprising intravenously).Therefore, pharmaceutical composition of the present invention can be the individual that is suitable for oral administration, for example capsule, cachet or tablet, and it contains the activeconstituents of predetermined amount respectively.In addition, said composition can also be the form of powder, granule, solution, waterborne liquid suspensoid, non-aqueous liquid suspensoid, oil-in-water emulsion or water-in-oil liquid emulsion.Except that above-mentioned general formulation, compound or the acceptable salt of its medicine represented by formula I also can carry out administration by controlled release mode and/or drug delivery systems.Described composition can be by any method of pharmacy preparation.Generally speaking, these methods comprise activeconstituents and the carrier blended step that must be become branch to be made up of one or more.Generally speaking, by both mix and prepare described composition with activeconstituents and liquid vehicle or micro-solid carrier or they.Then, product can be made required face shaping easily.

Therefore, pharmaceutical composition of the present invention can comprise compound or the acceptable salt of its medicine of medicine acceptable carrier and formula I.Can also comprise formula I compound or the acceptable salt of its medicine and one or more other therapeutical active compound in the described pharmaceutical composition.

Used pharmaceutical carrier can be for example solid, liquid or gas.The example of solid carrier comprises lactose, terra alba, sucrose, talcum powder, gelatin, agar, pectin, gum arabic, Magnesium Stearate and stearic acid.The example of liquid vehicle comprises syrup, peanut oil, sweet oil and water.The example of carrier gas comprises carbonic acid gas and nitrogen.

When the composition of preparation oral dosage form, can use any drug media easily.For example water, ethylene glycol, oil, ethanol, correctives, sanitas, tinting material etc. prepare oral liquid, for example suspensoid, elixir and solution etc.; And carriers such as starch, sugar, Microcrystalline Cellulose, thinner, granulation agent, lubricant, tackiness agent, disintegrating agent for example can be used for preparing oral solid formulation, for example powder, capsule and tablet etc.The tablet of use solid medicinal carrier and capsule are owing to being easy to administration, so be preferred oral dosage units.Tablet can be chosen wantonly with standard water and become technology coatings or non-water to become technology coatings.

Can suppress or the molded tablet that contains the present composition for preparing with one or more auxiliary agents or auxiliary material by optional.The activeconstituents that exists with free-flowing form is powder or particle etc. for example, and is optional with after tackiness agent, lubricant, inert diluent, tensio-active agent or dispersion agent etc. mix, and makes compressed tablets by compression in suitable machine.Through the mixture of the moistening powder compound of inert liquid diluent, in suitable machine, make molded tablet by pressing mold.Each tablet preferably contains the 0.1mg that has an appointment to the activeconstituents of about 500mg, and every cachet or capsule preferably contain the extremely activeconstituents of about 500mg of 0.1mg of having an appointment.Therefore; tablet, cachet or capsule can contain the activeconstituents of 0.1mg, 1mg, 5mg, 25mg, 50mg, 100mg, 200mg, 300mg, 400mg or 500mg easily; oral every day 1 time, 2 times or 3 times; each 1 or 2 of tablet, perhaps cachet or capsule are each 1 or 2.

The pharmaceutical composition of the present invention that is suitable for parenteral admin can be with active compound solution or the suspensoid made soluble in water.Can comprise suitable tensio-active agent, for example hydroxypropylcellulose.Prepare dispersion agent in the mixture in also available glycerine, liquid polyethylene glycol and its oil.In addition, can comprise sanitas to prevent the obnoxious growth of microorganism.

The pharmaceutical composition of the present invention that is suitable for injection comprises sterile aqueous solution agent or dispersion agent.In addition, said composition can be the form of sterile powder injection, faces with before making aseptic parenteral solution or aseptic injection dispersion liquid.In all cases, final injection form must be aseptic, and must be fluid, thereby has easy injectivity.Described pharmaceutical composition must produce and holding conditions under stablize, and preferably should prevent for example contamination of bacterium and fungi of microorganism.Carrier can be solvent or dispersion medium, contains for example water, ethanol, polyvalent alcohol (for example glycerine, propylene glycol and liquid polyethylene glycol), vegetables oil and their suitable mixture.

Pharmaceutical composition of the present invention can be and is suitable for the local formulation of using, for example aerosol, ointment, ointment, lotion, face powder etc.In addition, said composition can be the form that is applicable to transdermal device.Can use compound or the acceptable salt of its medicine represented by formula I among the present invention, the working method by routine prepares these preparations.For example, ointment or ointment can be prepared as follows: by hydrophilic material and water and about 5% (weight) to the compound of about 10% (weight) are in the same place, prepare the ointment or the ointment of required denseness.

Pharmaceutical composition of the present invention can be the form that is suitable for rectal administration, and wherein carrier is a solid.Preferred mixture forms unitary dose suppository.Suitable carriers comprises theobroma oil and this area other material commonly used.Can be by earlier composition being mixed with softening carrier or fusing carrier, then through cooling, and suppository is made in shaping easily in mould.

Except the aforementioned bearer composition, above-mentioned pharmaceutical preparation can comprise the additional carrier composition that one or more are suitable, for example thinner, buffer reagent, correctives, tackiness agent, tensio-active agent, thickening material, lubricant, sanitas (comprising antioxidant) etc.In addition, can also comprise that other auxiliary material is to provide and the isoosmotic preparation of recipient's blood.Contain the composition of formula I compound or the acceptable salt of its medicine, also can be made into pulvis or liquid concentration form.

Have been found that compound of the present invention and pharmaceutical composition show the biological activity as the mGluR5 inhibitor.Therefore, another aspect of the present invention is by giving the The compounds of this invention of significant quantity, treat diseases such as mammiferous schizophrenia, anxiety disorder, dysthymia disorders, panic disorder, bipolar disorder, diel rhythm obstacle and somnopathy, pain, Parkinson's disease, cognition dysfunction, epilepsy, dopy, drug abuse and drug withdrawal syndrome, described disease improves by suppressing mGluR5.Term " Mammals " comprises the mankind and other animal, for example dog, cat, horse, pig and ox.Therefore, people know, are exactly to the treatment of diseases relevant clinically with the example of disease that those above-mentioned people take a disease to the mammiferous treatment except the people.

In addition, as mentioned above, compound of the present invention can be treated compound with other and be united use.Specifically, mGluR5 of the present invention suppresses compound can advantageously unite use with following compound: i) opiate agonist or antagonist, ii) calcium-channel antagonists, iii) 5HT receptor stimulant or antagonist, iv) sodium channel antagonist, v) nmda receptor agonist or antagonist, vi) COX-2 selective depressant, vii) NK1 antagonist, viii) NSAID (non-steroidal anti-inflammatory drug) (" NSAID "), ix) GABA-A receptor modulators, x) dopamine agonist or antagonist, xi) selectivity serotonin reuptake inhibitor (" SSRI ") and/or selectivity serotonin and norepinephrine reuptake inhibitor (" SSNRI "), xii) tricyclic antidepressant, xiii) norepinephrine conditioning agent, xiv) L-DOPA, xv) buspirone, xvi) lithium salts, xvii) valproate, xviii) gabapentin, xix) olanzapine, xx) comprise the nicotinic agonist or the antagonist of Nicotine, xxi) muscarinic agonist or antagonist, xxii) heroine substitutes for example methadone of medicine, left-handed-α-Methadyl Acetate; buprenorphine and TREXUPONT, and xxiii) abstinence from alcohol sulphur and acamprosate.

The implication of abbreviation used herein sees the following form.The implication of the abbreviation that following table is not enumerated is identical with implication commonly used, except as otherwise noted.

Ac	Ethanoyl
Ac	Ethanoyl	AIBN	2,2 '-Diisopropyl azodicarboxylate
BINAP	1,1 '-two (beta naphthals)	AIBN	2,2 '-Diisopropyl azodicarboxylate
BINAP	1,1 '-two (beta naphthals)	Bn	Benzyl
CAMP	Ring gland glycosides-3 ', 5 '-one phosphoric acid	Bn	Benzyl
CAMP	Ring gland glycosides-3 ', 5 '-one phosphoric acid	DAST	Three fluoridize (diethylin) sulphur
DEAD	The diethylazodicarboxylate	DAST	Three fluoridize (diethylin) sulphur
DEAD	The diethylazodicarboxylate	DBU	1,8-diazabicyclo [5.4.0]-11 carbon-7-alkene
DIBAL	Diisobutylaluminium hydride	DBU	1,8-diazabicyclo [5.4.0]-11 carbon-7-alkene
DIBAL	Diisobutylaluminium hydride	DMAP	4-(dimethylamino) pyridine
DMF	N, dinethylformamide	DMAP	4-(dimethylamino) pyridine
DMF	N, dinethylformamide	dppf	1,1 '-two (diphenyl phosphine)-ferrocene
EDCI	1-(3-dimethylamino-propyl)-3-ethyl-carbodiimide hydrochloride	dppf	1,1 '-two (diphenyl phosphine)-ferrocene
EDCI		Et ₃N	Triethylamine
GST	Thiadiazolidine isomerase	Et ₃N	Triethylamine
GST	Thiadiazolidine isomerase	HMDS	Hexamethyl two silicon acid amides
LDA	Lithium diisopropylamine	HMDS	Hexamethyl two silicon acid amides
LDA	Lithium diisopropylamine	m-CPBA	Metachloroperbenzoic acid

MMPP	Monoperphthalic acid
MMPP	Monoperphthalic acid	MPPM	Monoperphthalic acid magnesium salts 6H ₂O
Ms	Methylsulfonyl=mesyl=SO ₂Me	MPPM	Monoperphthalic acid magnesium salts 6H ₂O
Ms	Methylsulfonyl=mesyl=SO ₂Me	Ms0	Methanesulfonates=mesylate
NBS	N-bromosuccinimide	Ms0	Methanesulfonates=mesylate
NBS	N-bromosuccinimide	NSAID	NSAID (non-steroidal anti-inflammatory drug)
o-Tol	The o-Xylol base	NSAID	NSAID (non-steroidal anti-inflammatory drug)
o-Tol	The o-Xylol base	OXONE	2KHSO ₅·KHSO ₄·K ₂SO ₄
PCC	Pyridinium chlorochromate	OXONE	2KHSO ₅·KHSO ₄·K ₂SO ₄
PCC	Pyridinium chlorochromate	Pd ₂(dba) ₃	Two (dibenzalacetones) close palladium (0)
PDC	The dichromic acid pyridine	Pd ₂(dba) ₃	Two (dibenzalacetones) close palladium (0)
PDC	The dichromic acid pyridine	PDE	Phosphodiesterase
Ph	Phenyl	PDE	Phosphodiesterase
Ph	Phenyl	Phe	Benzene two bases
PMB	To methoxy-benzyl	Phe	Benzene two bases
PMB	To methoxy-benzyl	Pye	Pyridine two bases
r.t.	Room temperature	Pye	Pyridine two bases
r.t.	Room temperature	Rac.	Racemic
SAM	Sulfamyl or sulphonamide or SO ₂NH ₂	Rac.	Racemic
SAM	Sulfamyl or sulphonamide or SO ₂NH ₂	SEM	2-(trimethyl silyl) oxyethyl group methoxy base
SPA	Scintillation proximity assay	SEM	2-(trimethyl silyl) oxyethyl group methoxy base
SPA	Scintillation proximity assay	TBAF	Fluoridize the tetra-n-butyl ammonium
Th	2-thienyl or 3-thienyl	TBAF	Fluoridize the tetra-n-butyl ammonium
Th	2-thienyl or 3-thienyl	TFA	Trifluoroacetic acid
TFAA	Trifluoroacetic anhydride	TFA	Trifluoroacetic acid
TFAA	Trifluoroacetic anhydride	THF	Tetrahydrofuran (THF)
Thi	Thiophene two bases	THF	Tetrahydrofuran (THF)

TLC	Tlc
TLC	Tlc	TMS-CN	The cyaniding trimethyl silane
TMSI	The iodate trimethyl silane	TMS-CN	The cyaniding trimethyl silane
TMSI	The iodate trimethyl silane	Tz	1H (or 2H)-tetrazolium-5-base
XANTPHOS	4, two (the phenylbenzene phosphinylidynes)-9 of 5-, 9-dimethyl-9H-xanthene	Tz	1H (or 2H)-tetrazolium-5-base
XANTPHOS		C ₃H ₅	Allyl group

The alkyl abbreviation

Me	＝	Methyl
Me	＝	Methyl	Et	＝	Ethyl
n-Pr	＝	N-propyl	Et	＝	Ethyl
n-Pr	＝	N-propyl	i-Pr	＝	Sec.-propyl
n-Bu	＝	Normal-butyl	i-Pr	＝	Sec.-propyl
n-Bu	＝	Normal-butyl	i-Bu	＝	Isobutyl-
s-Bu	＝	Sec-butyl	i-Bu	＝	Isobutyl-
s-Bu	＝	Sec-butyl	t-Bu	＝	The tertiary butyl
c-Pr	＝	Cyclopropyl	t-Bu	＝	The tertiary butyl
c-Pr	＝	Cyclopropyl	c-Bu	＝	Cyclobutyl
c-Pen	＝	Cyclopentyl	c-Bu	＝	Cyclobutyl
c-Pen	＝	Cyclopentyl	c-Hex	＝	Cyclohexyl

Prove bioactive test

To the anti-l cell Ltk of compound of the present invention ^-The hmGluR5a acceptor of stably express is tested in the cell (hmGluR5a/L38-20 clone), uses Ca ⁺⁺[the Ca that susceptibility fluorescence dye fura-2 measures ⁺⁺] _iChange and measure activity.L cell Ltk with stably express hmGluR5a ^-Cell (LM5a clone) carries out the InsP test.Can use the assay method of describing among the International Patent Publication No. W WO 0116121.

Calcium current goes out test

To the anti-l cell Ltk of compound ^-The activity of the hmGluR5a acceptor of stably express detects in the cell (hmGluR5a/L38 clone).Generally referring to Daggett etc., Neuropharmacology 34:871-886 (1995).The cellular calcium ([Ca that uses calcium sensitivity fluorescence dye fura-2 to measure ²⁺] _i) change and measure receptor active.The hmGluR5a/L38-20 cell inoculation in 96 orifice plates, is added 3 μ M fura-2, hatched 1 hour.Do not mix dyestuff in the flush away cell, with cell plate move to 96 pipe photofluorometers (SIBIA-SAIC, La Jolla, CA) under, this photofluorometer fuses with full-automatic plate operating system and liquid delivery system.With the xenon source that has spectral filter activated cell under 350nm and 385nm.Emission light by dichroic mirror and 510nm interference filter collected specimens also directly injects in the chilled CCD camera (Princeton Instruments) it.It is right approximately to capture image in per 1 second, draws scaled image behind the background deduction.Behind 20 seconds basic reading, in each hole, add EC ₈₀The L-glutamic acid of concentration (10 μ M), and reaction carried out making in 60 seconds evaluation again.([the Ca that L-glutamic acid caused when SCREENED COMPOUND was existed ²⁺] _i) reaction (positive control) that increases when only L-glutamic acid being arranged compares.

Phosphatidylinositols hydrolysis (PI) test

Method [Berridge etc., Biochem.J.206:587-5950 (1982) with descriptions such as Berridge; With Nakajima etc., J.Biol.Chem.267:2437-2442 (1992)] slightly modified carries out the inositol monophosphate test.The l cell Ltk cell (hmGluR5/L38-20 cell) of expressing hmGluR5 is inoculated in 24 orifice plates, and its density is 8 * 10 ⁵Cells/well.In each hole, add 1 μ Ci[ ³H]-inositol (Amersham PT6-271; Arlington Heights, Ill.; Than live=17.7Ci/mmol), hatching 16 hours in 37 ℃.With 0.5ml standard Hepes buffering salt damping fluid (HBS:125mM NaCl, 5mM KCl, 0.62mM MgSO ₄, 1.8mMCaCl ₂, 20mM HEPES, 6mM glucose, pH to 7.4) washed cell twice, hatched 45 minutes.Cell adds 400 μ L damping fluids then with the HBS washing that contains 10mM LiCl in every hole.Cell was hatched 20 minutes in 37 ℃.In order to test, to add the 10X compound (with HBS/LiCl (100mM) preparation) of the actual use of 50 μ L the present invention and hatched 10 minutes.By adding 10 μ M L-glutamic acid activating cellss, each plate was placed 1 hour in 37 ℃.Adding 1ml in each hole finishes to hatch with ice-cooled methyl alcohol.In order to separate inositol monophosphate (IP), from each hole, scrape cell, put it in the numbered glass test tube.Every test tube adds the 1ml chloroform, test tube is mixed, by each phase of centrifugation.Isolate IP through Dowex anion-exchange column (AG1-X8 100-200 order formic acid type).(750 μ L) joins in the Dowex post with top water layer, and pillar carries out wash-out with 3ml distilled water.Abandon elutriant, wash post with 10ml 60mM ammonium formiate/5mM borax again, discard elutriant equally.At last, pillar 4ml 800mM ammonium formiate/0.1M formic acid wash-out, sample collection is in the flicker bottle.Add scintillation solution in each bottle, shake the flicker bottle, count with scintillometer after 2 hours.Phosphatidylinositols hydrolysis in the cell that will handle with some exemplary compounds compares with the phosphatidylinositols hydrolysis in the cell that does not have compound treatment with only agonist being arranged.

The compound of asking in this has mGluR5 and suppresses active, goes out in the test its IC at calcium current ₅₀Value perhaps in the PI test, suppresses＞50% when its concentration is 100 μ M less than 10 μ M.Preferred the application's compound goes out IC in the test at calcium current ₅₀Value should be less than 1 μ M, and in the PI test IC ₅₀Value should be less than 10 μ M.Even more preferably the application's compound goes out IC in the test at calcium current ₅₀Value should be less than 100nM, and in the PI test IC ₅₀Value should be less than 1 μ M.

Embodiment 1-10 has mGluR5 and suppresses active, goes out in the test its IC at calcium current ₅₀Value is 10 μ M or better, and/or in the PI test, suppresses＞50% when its concentration is 100 μ M.

Following embodiment is used to illustrate some preferred embodiment of the present invention, limitation of the present invention anything but.

Except as otherwise noted, otherwise experimental arrangement under following condition, carry out.All operations all carries out under room temperature or envrionment temperature, promptly carries out in 18-25 ℃ temperature range.When bath temperature reaches 60 ℃, with rotatory evaporator the decompression (600-4000 handkerchief: carry out solvent evaporation 4.5-30mmHg).Use thin-layer chromatography (TLC) after the reaction process, the reaction times that provides only is used for explanation.Fusing point is not calibrated, and ' d ' represents to decompose.The fusing point that provides is to obtain from the material by described method preparation.Some the preparation in, polymorphism can cause isolating material have different fusing points.The structure of all final products and purity obtain conclusive evidence by following at least a kind of technology: TLC, mass spectroscopy, nucleus magnetic resonance (MR) spectral method or trace analysis data.When reporting the result, yield only is used for explanation.When reporting the result, the NMR data are used with respect to ppm (ppm) expression as interior target tetramethylsilane (TMS) for identifying that mainly proton is a δ value form, measure at 300MHz, 400MHz or 500MHz with the indication solvent.The employed conventional abbreviation of signal waveform is: s. is unimodal; D. bimodal; T. triplet; M. multiplet; Br. broad peak; Or the like.In addition, " Ar " expression aromatic signal.Chemical symbol is its implication commonly used, can use following abbreviation: v (volume), w (weight), b.p. (boiling point), m.p. (fusing point), L (liter), ml (milliliter), g (gram), mg (milligram), mol (mole), mmol (mmole), eq (equivalent).

Synthetic method

Can prepare compound of the present invention according to the following method shown in the following reaction scheme.Therefore, the invention provides the preparation method of new heteroaryl substituted triazole compounds.Available synthesising chemical technology well-known in the art is (referring to Comprehensive HeterocyclicChemistry, Katritzky, A.R. and Rees, C.W. write, Pergamon Press, Oxford, 1984), by heteroaryl substituted triazole of the present invention (formula (I)) beginning, prepare new heterogeneous ring compounds more of the present invention.

In scheme 1-10, unless otherwise defined, otherwise substituting group and formula I's is identical.Therefore, in the following proposal 1, the definition of X and Y is the same.Based on context to the substituent description of formula (I) or obtain formula (I) substituting group, substituting group is R for example ₁And R ₂All be clearly.

Scheme 1

Therefore, in scheme 1, in 0 ℃ to 100 ℃ temperature range, preferred 25 ℃ at present, at suitable solvent (for example EtOH, MeOH, iPrOH, H ₂O etc.) in, make the nitrile part (with synthesising chemical technology preparation well-known in the art) that contains ring system X react the enough time (about usually 12-18 hour) with hydrazine hydrate, obtain the substituted-amino hydrazone derivative (referring to for example Hage, R. etc., J.Chem.Soc.Dalton Trans.1987,1389-1395).Then, at appropriate condition (for example hot HCO ₂H or add the alkyl orthoformate of catalytic amount acid) under, make the cyclisation of gained amidrazone, mono-substituted 1,2 shown in obtaining, the 4-triazole derivative (referring to Sugiyarto, J.H. etc., Aust.J.Chem.1995,48,35-54 and Beck, J.R.; Babbitt, G.E.; Lynch, M.P.J.Heterocyclic Chem.1988,25,1467-1470).

Shown in scheme 1, then, can make gained 1,2,4-triazole and the Y material coupling that is replaced by the W group.W can be a nonmetallic substance, for example B (OR) ₂, BiLn etc., can be with the metal-salt of stoichiometry or catalytic amount Cu (OAc) for example ₂, CuI or CuOTf etc. promote this reaction.Usually, also there are alkali (for example pyridine, NEt ₃, Cs ₂CO ₃, K ₂CO ₃Deng), at suitable solvent (for example DCM, THF, DME, toluene, MeCN, DMF, H ₂O etc.) carry out this reaction in.In addition, can with molecular sieve as promotor (referring to for example Fedorov, A.Y.; Finet, J-P.Tetrahedron Lett.1999,40,2747-2748).Perhaps, W also can be halogen or can carry out other functional group of metal catalytic N-arylation cross-coupling reaction.In the case, also can add other promotor in the reaction mixture, for example 1,10-phenanthroline and dibenzalacetone.Can or be heated in envrionment temperature and carry out this cross-coupling reaction in about 30 ℃ to 150 ℃ temperature range.Then, reaction mixture remained on reach about 4 hours to 72 hours under the suitable temperature, usually about 18 hours just enough.The product of this reaction can with standard techniques such as solvent extration, chromatography, crystallization process, distillation method carry out separation and purification (referring to for example Lam, P.Y.S.; Clark, C.G.; Saubern, S.; Adams, J.; Winters, M.P.; Cham, D.M.T.; Combs, A.Tetrahedron Lett.1998,39,2941-2944 and Kiyomori, A.; Marcoux, J.F.; Buchwald, S.L.Tetrahedron Lett.1999,40,2657-2660).

In another embodiment of the invention, if W is good aryl leavings group, F for example, Y are the electron deficiency group or have one or more electron-withdrawing substituents (NO for example ₂, CN etc.), can to about 250 ℃ temperature range internal heating condition, finish this linked reaction at about 60 ℃.Usually, at alkali (for example pyridine, NEt ₃, Cs ₂CO ₃, K ₂CO ₃Deng) exist down, at suitable solvent for example DMSO, DMF, DMA H ₂Carry out this reaction among the O etc., the reaction times is 1 hour to about 72 hours, and common 18 hours just enough (referring to for example Russell, S.S.; Jahangir; Synth.Commun.1994,24,123-130).

In another embodiment of the invention, compound of the present invention can be by preparation shown in the following scheme 2.

Scheme 2

In scheme 2, use the synthetic chemistry identical, but nitrile functionality links to each other W and ring system X bonding with Y group at this moment with scheme 1.The product of scheme 1 and scheme 2 is promptly two to replace 1,2, and the 4-triazole can be carried out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillations.

In another embodiment of the invention, compound of the present invention can be by preparation shown in the following scheme 3.

Scheme 3

Therefore, make 3-bromo-1,2, the 4-triazole (prepares (referring to for example Bagal, L.I. etc. by the well-known synthetic chemistry of those skilled in the art, Khim.Geterotsikl.Soedin.1970,6,1701-1703)) and, obtain halogenation 1 by the X material coupling that the W group replaces, 2, the 4-triazole derivative.W can be a nonmetallic substance, for example B (OR) ₂, BiLn etc., can be with the metal-salt of stoichiometric metal-salt or catalytic amount Cu (OAc) for example ₂, CuI or CuOTf etc. promote this reaction.Usually, also there are alkali (for example pyridine, NEt ₃, Cs ₂CO ₃, K ₂CO ₃Deng), at suitable solvent (for example DCM, THF, DME, toluene, MeCN, DMF, H ₂O etc.) carry out this reaction in.In addition, can with molecular sieve as promotor (referring to for example Fedorov, A.Y.; Finet, J-P.Tetrahedron Lett.1999,40,2747-2748).

Perhaps, W also can be other functional group of halogen or the N-arylation cross-coupling reaction that can carry out metal catalytic, in the case, also can add other promotor in the reaction mixture, for example 1, and 10-phenanthroline and dibenzalacetone.Can or be heated in envrionment temperature and carry out this cross-coupling reaction in about 30 ℃ to 150 ℃ temperature range.Then, reaction mixture remained on reach about 4 hours to 72 hours under the suitable temperature, usually about 18 hours just enough (referring to for example Lam, P.Y.S.; Clark, C.G.; Saubern, S.; Adams, J.; Winters, M.P.; Cham, D.M.T.; Combs, A.Tetrahedron Lett.1998,39,2941-2944 and Kiyomori, A.; Marcoux, J.F.; Buchwald, S.L.TetrahedronLett.1999,40,2657-2660).

In another embodiment of the invention, if W is good aryl leavings group, F for example, Y are the electron deficiency group or have one or more electron-withdrawing substituents (NO for example ₂, CN etc.), can to about 250 ℃ temperature range internal heating condition, finish this linked reaction at about 60 ℃.Usually, at alkali (for example pyridine, NEt ₃, Cs ₂CO ₃, K ₂CO ₃Deng) exist down, at suitable solvent for example DMSO, DMF, DMA H ₂Carry out this reaction among the O etc., the reaction times is 1 hour to about 72 hours, and common 18 hours just enough (referring to for example Russell, S.S.; Jahangir; Synth.Commun.1994,24,123-130).The product of this reaction can carry out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

Then, under the cross-coupling condition of metal catalytic, make the halogenation 1,2 of preparation in the scheme 3,4-triazole derivative and Y material react, and wherein E is the metal or the nonmetallic substance that can carry out the cross-coupling reaction of metal catalytic, for example B (OR) ₂, Li, MgHal, SnR ₃, ZnHal, SiR ₃Deng.At suitable solvent (for example THF, DME, toluene, MeCN, DMF, H ₂O etc.) in, can be with homogeneous catalyst Pd (PPh for example ₃) ₄Perhaps with heterogeneous catalyst for example Pd/C promote this coupling.Usually, in reaction mixture, also can there be for example K of alkali ₂CO ₃, NEt ₃Deng.Also can use other promotor, for example CsF.Usually, make temperature of reaction in several hours, slowly rise to room temperature and just can carry out this linked reaction from about 0 ℃.Then reaction mixture is kept at ambient temperature, perhaps be heated to the temperature between 30 ℃ to 150 ℃.Then reaction mixture is remained on and reaches about 4 hours to 48 hours under the suitable temperature, usually about 18 hours just enough (referring to for example Miyaura, N.; Suzuki, A.Chem.Rev.1995,95,2457-2483).The product of this reaction can carry out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

In another embodiment of the invention, compound of the present invention can be by preparation shown in the following scheme 4.

Scheme 4

In scheme 4, use the synthetic chemistry identical, but W functional group is connected E and X ring system bonding with Y group at this moment with scheme 3.The product of scheme 4 is two to replace 1,2, and the 4-triazole can be carried out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

Another embodiment of the invention is shown in following scheme 5.

Scheme 5

Therefore, in scheme 5, it can be the G functional group of alkynyl or 2-nitroethylene base section that X material (available method preparation well-known in the art) comprises.In suitable solvent (for example toluene, benzene, dimethylbenzene etc.), about 25 ℃ to about 180 ℃ temperature range, make partly LiN for example of X material and trinitride ₃, NaN ₃Or TMSN ₃Reaction generates single substituted triazole.This reaction usually for example carry out in the presence of tetrabutylammonium or the dibutyl tin oxide at additional catalyst (referring to for example Moltzen, E.K.; Pedersen, H.; Boegesoe, K.P.; Meier, E.; Frederiksen, K.J.Med.Chem.1994,37,4085-4099).

In one embodiment, compound of the present invention prepares according to following proposal 6:

Scheme 6

Then, can make the product 1,2,3-triazoles and the Y material coupling that is replaced by the W group of scheme 5 gained.W can be a nonmetallic substance, for example B (OR) ₂, BiLn etc.; Can be with the metal-salt of stoichiometric metal-salt or catalytic amount Cu (OAc) for example ₂, CuI or CuOTf etc. promote this reaction.Usually, also there are alkali (for example pyridine, NEt ₃, Cs ₂CO ₃, K ₂CO ₃Deng), at suitable solvent (for example DCM, THF, DME, toluene, MeCN, DMF, H ₂O etc.) carry out this reaction in.In addition, can with molecular sieve as promotor (referring to for example Fedorov, A.Y.; Finet, J-P.Tetrahedron Lett.1999,40,2747-2748).

Perhaps, W also can be other functional group of halogen or the N-arylation cross-coupling reaction that can carry out metal catalytic, in the case, also can add other promotor in the reaction mixture, for example 1, and 10-phenanthroline and dibenzalacetone.Can or be heated in envrionment temperature and carry out this cross-coupling reaction in about 30 ℃ to 150 ℃ temperature range.Then, reaction mixture remained on reach about 4 hours to 72 hours under the suitable temperature, usually about 18 hours just enough (referring to for example Lam, P.Y.S.; Clark, C.G.; Saubern, S.; Adams, J.; Winters, M.P.; Cham, D.M.T.; Combs, A.Tetrahedron Lett.1998,39,2941-2944 and Kiyomori, A.; Marcoux, J.F.; Buchwald, S.L TetrahedronLett.1999,40,2657-2660).

The product of scheme 6 i.e. two kinds of two 1,2,3-triazoles that replace of isomer, can carry out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

Another embodiment of the invention is shown in following scheme 7 and scheme 8:

Scheme 7

Therefore, in scheme 7, Y material (available method preparation well-known in the art) contains the G functional group that can be alkynyl or 2-nitroethylene base section.In suitable solvent (for example toluene, benzene, dimethylbenzene etc.), about 25 ℃ to about 180 ℃ temperature range, make partly LiN for example of Y material and trinitride ₃, NaN ₃Or TMSN ₃Reaction generates single substituted triazole.This reaction usually for example carry out in the presence of tetrabutylammonium or the dibutyl tin oxide at additional catalyst (referring to for example Moltzen, E.K.; Pedersen, H.; Boegesoe, K.P.; Meier, E.; Frederiksen, K.J.Med.Chem.1994,37,4085-4099).

Scheme 8

Then, can make the 1,2,3-triazoles and the X material coupling (scheme 8) that is replaced by the W group of scheme 7 gained.W can be a nonmetallic substance, for example B (OR) ₂, BiLn etc.; Can be with the metal-salt of stoichiometric metal-salt or catalytic amount Cu (OAc) for example ₂, CuI or CuOTf etc. promote this reaction.Usually, also there are alkali (for example pyridine, NEt ₃, Cs ₂CO ₃, K ₂CO ₃Deng), at suitable solvent (for example DCM, THF, DME, toluene, MeCN, DMF, H ₂O etc.) carry out this reaction in.In addition, can with molecular sieve as promotor (referring to for example Fedorov, A.Y.; Finet, J-P.Tetrahedron Lett.1999,40,2747-2748).

The product of scheme 8 i.e. two kinds of two 1,2,3-triazoles that replace of isomer, can carry out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

Another embodiment of the present invention is shown in following scheme 9:

Scheme 9

In scheme 9, single substituted triazole is by scheme 5 preparations.Then, in-100 ℃ to 50 ℃ temperature range, preferred-78 ℃ to 23 ℃ at present, in the presence of suitable alkali (for example MeONa, EtONa, tBuOK etc.), make gained triazole and N-fluorine pyridinium salt (can be optionally substituted) reaction about 1-12 hour (referring to for example Kiselyov, A.S. and Strekowski, L..J.Heterocyclic Chem.1993,30,1361-1364).The product of scheme 9 is an isomer 2-pyridyl triazole derivative, can carry out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

Another embodiment of the present invention is shown in following scheme 10:

Scheme 10

In scheme 10, single substituted triazole is by scheme 7 preparations.Then, in-100 ℃ to 50 ℃ temperature range, preferred-78 ℃ to 23 ℃ at present, in the presence of suitable alkali (for example MeONa, EtONa, tBuOK etc.), make gained triazole and N-fluorine pyridinium salt (can be optionally substituted) reaction about 1-12 hour (referring to for example Kiselyov, A.S. and Strekowski, L..J.Heterocyclic Chem.1993,30,1361-1364).The product of scheme 10 is an isomer 2-pyridyl triazole derivative, can carry out separation and purification with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method.

In such scheme, ring system X and/or Y can contain side ring W and/or Z.Yet if desired, ring system W and/or Z can distinguish side joint X and/or Y, and wherein G and/or J are functional group (for example halogen, triflate, the B (OR) of the cross-coupling that can experience metal catalytic ₂, ZnX, SnR ₃Deng-following scheme 11).Ring system W and Z are all replaced by group P, Q, S and T, and described group can be for example halogen, triflate, B (OR) ₂, ZnX, SnR ₃Deng.Usually, can use for example Pd (PPh of transition-metal catalyst ₃) ₄, Pd (PPh ₃) ₂Cl ₂, Pd (OAc) ₂, NiCl ₂(dppe), Pd (OAc) ₂, Pd ₂(dba) ₃, Cu (OAc) ₂, CuI etc. and suitable alkali K for example ₂CO ₃, K ₃PO ₄, Cs ₂CO ₃, Et ₃N, pyridine etc.In addition, can add part for example BINAP, di-t-butyl phosphino-xenyl, dicyclohexyl phosphino-xenyl, tri-butyl phosphine, XANTPHOS, triphenylarsine etc.For example in the combination of toluene, DME, diox, THF, water or mentioned reagent, 50 ℃-150 ℃ heating 1-48 hour, carry out this reaction at suitable solvent usually.This reactant can be a homogeneous or heterogeneous (referring to for example Miyaura, N.; Suzuki, A.Chem.Rev.1995,95,2457-2483; And Dai, C.; Fu, G.C.J.Am.Chem.Soc., 2001,123,2719-2724; And Littke, A.F.; Fu, G.C.Angew.Chem.Int.Ed.1999,38,6,2411-2413; And Dai, C; Fu, G.C.J.Am.Chem.Soc.2001,123,2719-2724).

Scheme 11

Perhaps, ring system W or Z can be nitrogen heterocyclic rings, and wherein this nitrogen is directly connected to ring system X or Y respectively.In the case, G and/or J are the group that can experience the N-aryl cross-coupling of metal catalytic (for example halogen, triflate, B (OR) ₂, ZnX, SnR ₃Deng-scheme 6).Usually, can use transition metal for example CuI, Cu (OAc) ₂, Cu (OTf) ₂, Pd (PPh ₃) ₄, Pd (PPh ₃) ₂Cl ₂, Pd (OAc) ₂, Pd ₂(dba) ₃, NiCl ₂(dppe) and suitable alkali K for example ₂CO ₃, K ₃PO ₄, Cs ₂CO ₃, NaOtBu etc.In addition, can add and contain phosphine part for example BINAP, di-t-butyl phosphino-xenyl, dicyclohexyl phosphino-xenyl, tri-butyl phosphine, XANTPHOS etc.In addition, can use additive for example 1,10-phenanthroline, 1,2-diamino-cyclohexane, dibenzalacetone.For example in the combination of toluene, DME, diox, THF, water or mentioned reagent, 50 ℃-150 ℃ heating 1-48 hour, carry out this reaction at solvent usually.This reactant can be a homogeneous or heterogeneous.The product of scheme 11 can with standard techniques such as solvent extration, soda acid extraction process, chromatography, crystallization process, distillation method carry out separation and purification (referring to for example Lam, P.Y.S.; Clark, C.G.; Saubern, S.; Adams, J.; Winters, M.P.; Cham, D.M.T.; Combs, A.Tetrahedron Lett.1998,39,2941-2944; And Kiyomori, A.; Marcoux, J.F.; Buchwald, S.L.Tetrahedron Lett.1999,40,2657-2660; And Wolfe, J.P.; Tomori, H.; Sadighi, J.P.; Yin, J.; Buchwald, S.L.J.Org.Chem., 2000,65,1158-1174; And Yin, J.; Buchwald, S.L.; Org.Lett., 2000,2,1101-1104).

In addition, can be with other synthesising chemical technology well-known in the art (referring to Comprehensive Heterocyclic Chemistry, Katritzky, A.R. and Rees, C.W. write Pergamon Press, Oxford, 1984) reach the reference of wherein quoting, prepare many above-mentioned heterogeneous ring compounds.

Compound 1

1-(3-methoxyl group-4-pyridine-2-base phenyl)-2-nitroethyl alcohol

With 3-methoxyl group-4-pyridine-2-benzaldehyde (0.3g, 1.4mmol), Nitromethane 99Min. (0.23ml, 4.2mmol) and TEA (0.2ml, 1.4mmol) THF solution stir down at 55 ℃ and spend the night, concentrate,, obtain yellow foam through silica gel purification (2: 1 hexane-ethyl acetate).

Compound 2

The 2-{2-methoxyl group-4-[(Z)-2-nitroethylene base] phenyl } pyridine

1-(3-methoxyl group-4-pyridine-2-base phenyl)-2-nitroethyl alcohol (290mg, (0.24ml 1.69mmol) handles anhydrous methylene chloride 1.06mmol) (5ml) solution with triethylamine, use methylsulfonyl chloride (0.10ml afterwards, 1.27mmol) handle, after 1 hour, make mixture at saturated NaHCO ₃(10ml) and between the methylene dichloride (20ml) distribute.Separate each phase, water layer extracts with methylene dichloride (3x10ml).With the organic layer drying (MgSO that merges ₄), filter and concentrate, obtain yellow solid.

Compound 3

2-[2-methoxyl group-4-(1H-1,2,3-triazole)-4-base phenyl] pyridine

With 2-{2-methoxyl group-4-[(Z)-2-nitroethylene base] phenyl } pyridine (0.23g, 0.89mmol) and TMSN ₃(0.18ml, DMF 1.34mmol) (1ml) solution slowly is heated to 50 ℃, simultaneously in 20 minutes, drip TBAF (0.98ml, the THF solution of 1.0M, 0.98mmol).With the gained reaction mixture 50 ℃ of following continuously stirring 30 minutes.Make mixture at saturated NaHCO ₃(20ml) and between the EtOAc (60ml) distribute.Separate each phase, (3 * 60ml) extract water layer with EtOAc.With the organic layer drying (MgSO that merges ₄), filter and concentrate.Resistates obtains yellow solid through silica gel purification (20: 1 hexane-ethyl acetate).

Embodiment 1

2-[4-(3-methoxyl group-4-pyridine-2-base phenyl)-2H-1,2,3-triazole-2-yl] pyridine

To 2-[2-methoxyl group-4-(1H-1,2,3-triazole-4-yl) phenyl] (180mg in anhydrous MeOH solution 0.71mmol), adds Cs to pyridine ₂CO ₃(462mg, 1.42mmol) and trifluoromethanesulfonic acid 1-fluorine pyridine (350mg, 1.42mmol).The stirring of gained reaction mixture is spent the night.Mixture is distributed between the 10%NaOH aqueous solution (10ml) and EtOAc (60ml).Separate each phase, (3 * 60ml) extract water layer with EtOAc.With the organic layer drying (MgSO that merges ₄), filter and concentrate.Resistates obtains 2-[4-(3-methoxyl group-4-pyridine-2-base phenyl)-2H-1 through silica gel purification (20: 1 hexane-ethyl acetate), and 2,3-triazole-2-yl] pyridine, it is dissolved in the ether, add HCl (diethyl ether solution of 1N) then.Gained solution is filtered, obtain HCl salt, be white solid. ¹H NMR(500MHz，CD ₃OD)δ8.86-8.47(m，1H)，8.72-8.68(m，1H)，8.64-8.62(m，2H)，8.39-8.37(m，1H)，8.26-8.25(m，1H)，8.15-8.11(m，1H)，8.07-8.04(m，1H)，8.02(m，1H)，7.91-7.80(m，2H)，7.60(m，1H)。MS(ESI)330(M+H ⁺)。

Embodiment 2

2-[4-(3-methoxyl group-4-pyridine-2-base phenyl)-1H-1,2, the 3-triazol-1-yl] pyridine

2-[2-methoxyl group-4-(2-phenyl-2H-1 from above-mentioned reaction, 2,3-triazole-4-yl) phenyl] pyridine isolates title compound in (embodiment 1), obtain isomer 2-[4-(3-methoxyl group-4-pyridine-2-base phenyl)-1H-1,2, the 3-triazol-1-yl] pyridine, it is dissolved in the ether, add HCl (diethyl ether solution of 1N) then.Gained solution is filtered, obtain HCl salt, be white solid. ¹H NMR(500MHz，CD ₃OD)δ9.41(s，1H)，8.85-8.83(m，1H)，8.69-8.68(m，1H)，8.38-8.37(m，2H)，8.24(m，1H)，8.12-8.11(m，1H)，8.04(m，1H)，7.94(m，1H)，7.86-7.85(m，2H)，7.54(m，1H)。MS(ESI)330(M+H ⁺)。

The preparation of embodiment 3 to embodiment 10 shown in the following table is with above-mentioned scheme and step (ND=undetermined).

Conspicuous for those skilled in the art other variation or modification are all in scope of the present invention and disclosure.The present invention only is subjected to the restriction of claims scope.

Claims

1. compound or the acceptable salt of its medicine by following formula (I) expression:

Wherein:

W is-C _3-7Cycloalkyl ,-assorted C _3-7Cycloalkyl ,-C _0-6Alkylaryl or-C _0-6Miscellaneous alkyl aryl, they are optional separately by 1-7 independently following substituting group replacement: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _1-6Thiazolinyl ,-C _1-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ²R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ²

Any alkyl is optional by 1-5 independently halogenic substituent replacement;

Any N can be the N-oxide compound; With

One of W and Z are optional not to be existed.

2. the compound of claim 1 or the acceptable salt of its medicine, wherein:

X is the optional 2-pyridyl that is replaced by 1-4 independently following substituting group: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _2-6Thiazolinyl ,-C _2-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ², wherein optional two substituting groups are combined together to form and X condensed cycloalkyl ring or heterocycloalkyl ring; Wherein said-C _1-6Alkyl substituent, cycloalkyl ring or heterocycloalkyl ring are optional separately further to be replaced by 1-5 independently following group: halogen ,-CN ,-C _1-6Alkyl ,-O (C _0-6Alkyl) ,-O (C _3-7Cycloalkyl) ,-O (aryl) ,-O (heteroaryl) ,-N (C _0-6Alkyl) (C _0-6Alkyl) ,-N (C _0-6Alkyl) (C _3-7Cycloalkyl) or-N (C _0-6Alkyl) (aryl).

3. the compound of claim 1 or the acceptable salt of its medicine, wherein:

4. the compound of claim 1 or the acceptable salt of its medicine, wherein:

Z chooses wantonly by 1-7 independently following substituting group to replace-C _0-6Miscellaneous alkyl aryl: halogen ,-CN, NO ₂,-C _1-6Alkyl ,-C _1-6Thiazolinyl ,-C _1-6Alkynyl ,-OR ¹,-NR ¹R ²,-C (=NR ¹) NR ²R ³,-N (=NR ¹) NR ²R ³,-NR ¹COR ²,-NR ¹CO ₂R ²,-NR ¹SO ₂R ⁴,-NR ¹CONR ²R ³,-SR ⁴,-SOR ⁴,-SO ₂R ⁴,-SO ₂NR ¹R ²,-COR ¹,-CO ₂R ¹,-CONR ¹R ²,-C (=NR ¹) R ²Or-C (=NOR ¹) R ²R ¹¹For halogen ,-C _0-6Alkyl ,-C _0-6Alkoxyl group ,=O ,=N (C _0-4Alkyl) or-N (C _0-4Alkyl) (C _0-4Alkyl).

5. the compound of claim 1, described compound is made up of following compounds or the acceptable salt of its medicine:

1) 2-[4-(3-methoxyl group-4-pyridine-2-base phenyl)-2H-1,2,3-triazole-2-yl] pyridine;

2) 2-[4-(3-methoxyl group-4-pyridine-2-base phenyl)-1H-1,2, the 3-triazol-1-yl] pyridine;

3) 2-[4-(3-pyridine-2-base phenyl)-1H-1,2, the 3-triazol-1-yl] pyridine;

4) 2-[4-(3-pyridine-2-base phenyl)-2H-1,2,3-triazole-2-yl] pyridine;

5) 2-[4-(3-pyridin-3-yl phenyl)-1H-1,2, the 3-triazol-1-yl] pyridine;

6) 2-[4-(3-pyridin-3-yl phenyl)-2H-1,2,3-triazole-2-yl] pyridine;

7) 2-[4-(3-fluoro-4-pyridine-2-base phenyl)-1H-1,2, the 3-triazol-1-yl] pyridine;

8) 2-[4-(3-fluoro-4-pyridine-2-base phenyl)-2H-1,2,3-triazole-2-yl] pyridine;

9) 2-[2-methoxyl group-4-(5-methyl isophthalic acid-pyridine-2-base-1H-1,2,3-triazole-4-yl) phenyl] pyridine;

10) 2-[2-methoxyl group-4-(5-methyl-2-pyridine-2-base-2H-1,2,3-triazole-4-yl) phenyl] pyridine.

6. pharmaceutical composition, described composition comprises the compound or the acceptable salt of its medicine of the claim 1 for the treatment of significant quantity; And medicine acceptable carrier.

7. the pharmaceutical composition of claim 6, described composition also comprises: i) opiate agonist, ii) opiate antagonist, iii) calcium-channel antagonists, iv) 5HT receptor stimulant, v) 5HT receptor antagonist, vi) sodium channel antagonist, vii) nmda receptor agonist, viii) nmda receptor antagonist, ix) COX-2 selective depressant, x) NK1 antagonist, xi) NSAID (non-steroidal anti-inflammatory drug), xii) GABA-A receptor modulators, xiii) dopamine agonist, xiv) dopamine antagonist, xv) selectivity serotonin reuptake inhibitor, xvi) tricyclic antidepressant, xvii) norepinephrine conditioning agent, xviii) L-DOPA, xix) buspirone, xx) lithium salts, xxi) valproate, xxii) gabapentin, xxiii) olanzapine, xxiv) nicotinic agonist, xxv) nicotinic antagonists, xxvi) muscarinic agonist, xxvii) muscarine antagonist, xxviii) selectivity serotonin and norepinephrine reuptake inhibitor (SSNRI), xxix) heroine substitutes medicine, xxx) abstinence from alcohol sulphur, or xxxi) acamprosate.

8. it is methadone, left-handed-α-Methadyl Acetate, buprenorphine or TREXUPONT that the pharmaceutical composition of claim 7, wherein said heroine substitute medicine.

9. the compound of claim 1 is used for the treatment of purposes in the medicine of following disease in preparation: motion dysfunction, anxiety disorder, Parkinson's disease, dysthymia disorders, epilepsy, cognition dysfunction, dopy, diel rhythm obstacle and somnopathy and obesity outside painful diseases, the pyramidal tract.

10. the purposes of claim 9, wherein said painful diseases is acute pain, rest pain, chronic pain, inflammatory pain or neuropathic pain.

11. the compound of claim 1 is used for the treatment of purposes in the medicine of following disease in preparation: anxiety disorder, dysthymia disorders, bipolar disorder, psychosis, drug withdrawal syndrome, tobacco withdrawal syndrome, the loss of memory, cognitive decline, dementia, alzheimer's disease, schizophrenia or panic disorder.

12. the purposes of claim 9, the outer motion dysfunction of wherein said pyramidal tract is paralysis, Huntington Chorea (Huntington ' s disease), tourette's syndrome (Gilles de la Tourette syndrome) or a tardive dyskinesia on Parkinson's disease, the carrying out property flesh.